Email ID
Password
Scrip   
GSK files lapatinib for first-line metastatic breast cancer in US and EU
02 April 2009
Malini Guha

GlaxoSmithKline is hoping to expand the indication of Tykerb/Tyverb (lapatinib) to treat first-line metastatic breast cancer, submitting filings in both the US and the EU for patients with hormone-sensitive disease.

Lapatinib, a small molecule inhibitor of HER2 and EGFR, is so far approved...



Please Login to read the full article.
EVENTS
Today
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36